Biolinerx Stock Today

BLRX Stock  USD 3.16  0.11  3.61%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

High

 
High
 
Low
BioLineRx is trading at 3.16 as of the 16th of March 2025; that is 3.61 percent increase since the beginning of the trading day. The stock's open price was 3.05. BioLineRx has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
25th of July 2011
Category
Healthcare
Classification
Health Care
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.56 M outstanding shares of which 216.35 K shares are currently shorted by private and institutional investors with about 1.72 trading days to cover. More on BioLineRx

Moving together with BioLineRx Stock

  0.73ENVB Enveric Biosciences Earnings Call Next WeekPairCorr

Moving against BioLineRx Stock

  0.72ETON Eton PharmaceuticalsPairCorr
  0.66VIGL Vigil NeurosciencePairCorr
  0.54LLY Eli LillyPairCorr
  0.53NBY NovaBay Pharmaceuticals Earnings Call Next WeekPairCorr
  0.48IVA Inventiva SaPairCorr
  0.45MGTX MeiraGTx Holdings PLC Downward RallyPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

BioLineRx Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Vice President-DevelopmentElla Sorani
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.06010.0676
Fairly Down
Slightly volatile
Gross Profit Margin0.250.27
Significantly Down
Slightly volatile
Total Current Liabilities37.3 M35.5 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total24 M22.8 M
Sufficiently Up
Slightly volatile
Total Assets53.7 M73.5 M
Way Down
Slightly volatile
Total Current Assets40.4 M54.3 M
Way Down
Slightly volatile
Debt Levels
BioLineRx can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioLineRx's financial leverage. It provides some insight into what part of BioLineRx's total assets is financed by creditors.
Liquidity
BioLineRx currently holds 11.59 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. BioLineRx has a current ratio of 4.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BioLineRx's use of debt, we should always consider it together with its cash and equity.

Change To Account Receivables

(1.13 Million)
BioLineRx (BLRX) is traded on NASDAQ Exchange in USA. It is located in Modi?in Technology Park, Hevel Modi'in, Israel, 7177871 and employs 79 people. BioLineRx is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.24 M. BioLineRx conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.56 M outstanding shares of which 216.35 K shares are currently shorted by private and institutional investors with about 1.72 trading days to cover. BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9.
Check BioLineRx Probability Of Bankruptcy
Ownership Allocation
The market capitalization of BioLineRx is $11.24 Million. BioLineRx shows 4.67 percent of its outstanding shares held by insiders and 1.4 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check BioLineRx Ownership Details

BioLineRx Stock Institutional Holders

InstituionRecorded OnShares
Envestnet Asset Management Inc2024-12-31
0.0
Susquehanna International Group, Llp2024-12-31
0.0
Wells Fargo & Co2024-12-31
0.0
Cutter & Co Brokerage, Inc.2024-12-31
0.0
Atria Wealth Solutions, Inc.2024-12-31
0.0
Rathbone Brothers Plc2024-12-31
0.0
Morgan Stanley - Brokerage Accounts2024-12-31
0.0
Atria Investments Llc2024-12-31
0.0
Virtu Financial Llc2024-12-31
0.0
Values First Advisors Inc2024-12-31
166.4 K
Rhumbline Advisers2024-12-31
43 K
View BioLineRx Diagnostics

BioLineRx Historical Income Statement

At this time, BioLineRx's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 2.6 M in 2025, whereas Total Revenue is likely to drop slightly above 4.1 M in 2025. View More Fundamentals

BioLineRx Stock Against Markets

BioLineRx Corporate Management

CPA CPAChief OfficerProfile
Raziel FriedTreasurer DirectorProfile
Adam EsqGeneral ComplianceProfile
Jael MScQA RAProfile
CPA MBAChief OfficerProfile

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.